Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Review Acta Cardiol Sin 2007;23:211-24 Improving Care for Patients with Heart Failure: What Can Taiwan Accomplish? Shyh-Ming Chen,1 Mien-Cheng Chen1 and W. H. Wilson Tang2 Heart failure is a growing public health issue worldwide, due to the improved survival of patients with heart diseases and the increased complexity of treatment options. If unrecognized and inadequately treated, the disease burden of heart failure can be devastating and costly. This review will compare the similarities and differences in different aspects of contemporary care of the patient with heart failure between Taiwan and many Western societies. In addition, this review will also examine potential treatment modalities and approaches that can be adopted in Taiwan’s health care system, with the goal of bettering care for patients with heart failure in Taiwan. Key Words: Heart failure · Taiwan · Disease management program sis of heart failure still carries an abysmal prognosis.2 In a study of over 30,000 patients admitted with new-onset heart failure, the 30-day and one-year mortality rates were an 12% and 30%, respectively.3 Several new approaches, including drugs, devices, and surgical approaches, have been explored to combat heart failure. These treatment approaches have followed the evolution of the conceptual models created to understand the pathophysiology of heart failure. The increasing prevalence of heart failure in Taiwan may parallel with that seen in many Western countries. The expanding patient population, coupled with rapid growth in treatment options, demands the recognition of heart failure as an important subspecialty of cardiology, and an important target for quality improvement. The purpose of this paper is to critically evaluate the current status of heart failure epidemiology and care in Taiwan, and examine aspects of heart failure care in Western societies that can be applicable to Taiwan. INTRODUCTION Heart failure is a growing epidemic worldwide, owing to the aging population and the increasing survival of patients presenting with acute myocardial infarction and various other heart diseases. In the USA, heart failure has become one of the most common hospital discharge diagnoses in the elderly population, and has consumed a large proportion of total health care expenditure.1 Patients with heart failure may take on average 5-7 different medications. In many cases, patients with heart failure have to undergo expensive and risky diagnostic and therapeutic procedures. They are often restricted to living their lives in disability, with recurrent hospitalizations for decompensation that are costly to the society. Despite decades of therapeutic advances, the diagno- Received: June 28, 2007 Accepted: September 10, 2007 1 Division of Cardiology, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung, Taiwan; 2Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA. Address correspondence and reprint requests to: Dr. W. H. Wilson Tang, MD FACC FAHA, Department of Cardiovascular Medicine, Cleveland Clinic, 9500 Euclid Avenue, Desk F25, Cleveland, Ohio 44195, U.S.A. Tel: +1(216)444-2121; Fax: +1(216)445-6165; E-mail: [email protected] Differences between Taiwan and western countries in heart failure care Differences in heart failure epidemiology Although there have been limited data regarding the epidemiology of heart failure in Taiwan, previous reports have suggested that the annual mortality rate of pa211 Acta Cardiol Sin 2007;23:211-24 Shyh-Ming Chen et al. are fewer physicians and acute care beds, Taiwan’s existing infrastructure has provided a large volume of ambulatory care services and significant amount inpatient care10 (Figure 1). Taiwan’s health care system is recognized for its accessibility, low cost, and high degree of public satisfaction. However, there are several important challenges with respect to the emerging burden of heart failure. In particular, the amount of time and attention spent on each individual heart failure patient with respect to disease management is limited. Most doctors in Taiwan frequently neglect patients’ understanding of their disease and adherence to their prescribed medications. Interventions for dietary and lifestyle modification are not readily available. Since the health literacy and knowledge of self-care for patients with heart failure in Taiwan is relatively low, the lack of adequate patientoriented approaches may directly impact the effectiveness of treatment regimens. Genotype and racial difference Genetic determinants of the pathophysiology of heart failure are likely polygenic, and hence the relative contributions to environmental influences are complex. Though heart failure genomic information has not been widely utilized in clinical practice, there are many examples of how this information can potentially transform the way we look at the heart failure phenotype.11 Advances in “pharmacogenetics” rely on observations that involved specific patient populations, with particular genotypes responding differently to the same drug treat- tients with heart failure could be as high as 40-50% for New York Heart Association (NYHA) functional class III to IV patients who are waiting for cardiac transplantation.4,5 Additionally, the in-hospital mortality rate may be as high as 23.5%.4 These figures appear to be inferior when directly compared with those in Western societies, although no direct comparison has been made. Nevertheless, with an aging society and a medical system primarily geared towards reactive salvage as oppose to proactive prevention, the disease burden of heart failure in Taiwan is only going to increase. More recent data reported a prevalence of heart failure in a communitybased cohort of approximately 5.5%, with the majority being hypertension as etiology. The 5- and 10-year mortality ranged from 14% and 48.2% in those with impaired LVEF versus 14.1% and 24.4% in those with preserved LVEF, respectively.6 Overall, patients with heart failure in Taiwan have high prevalences of hypertension and diabetes mellitus as their comorbid conditions. With the growing influence of the Western diet and the high prevalence of cigarette smoking in Taiwan, myocardial infarction as the cause of heart failure is becoming increasingly common. We can witness how the epidemiological trends will go with a glimpse of heart failure epidemiology in many Western societies. Even with a strong emphasis in the interdisciplinary management of heart failure in the United States of America, there are still an estimated 5 million Americans suffering from heart failure and over 500,000 new cases diagnosed annually.7,8 A larger burden comes with the costly hospitalizations associated with heart failure exacerbations: approximately 1 million hospital admissions per year (a 174% increase from 1979 to 2003),7 and readmission rates as high as 30% at 3 months and 60% at 6 months following discharge.9 In particular, both concomitant atrial fibrillation and diabetes mellitus commonly occur in the heart failure population, and both are increasing in prevalence in the Taiwan population as well. This all translates into significant disease burden, large expenditures for heart failure diagnostic testing and treatments, and the desperate need to improve on existing diagnosis and management strategies. Health care system differences Compared to the OECD (Organisation for Economic Co-operation and Development) countries, Taiwan’s health care system is relatively efficient. Although there Acta Cardiol Sin 2007;23:211-24 Figure 1. Ambulatory care service in Taiwan and other OEDC countries in 1999. 212 Heart Failure Care in Taiwan their Western counterparts. Physicians operate largely on a paternalistic model without carefully explaining treatment options and providing the necessary counseling for dietary and lifestyle modifications. With the lack of understanding of the chronicity of the heart failure syndrome, many Taiwanese patients only seek the least amount of drugs or procedures to relieve symptoms,24 and often fail to understand their responsibilities to alter their long-term lifestyles or adhere to medical advices.25 They may also have a limited understanding of the gravity of the diagnosis when undertreated. These may translate into recurrent hospitalizations and unnecessary morbidity and mortality. ment. In some cases, the genetic heterogeneity may affect drug metabolism or clearance. For examples, the angiotensinogen gene haplotypes were associated with hypertension in Taiwanese patient, which may interfere with the treatment in heart failure patient.12,13 In other cases, the responses to therapy may differ, due to physiologic differences between polymorphisms of enzymes and metabolic pathways affected. Previous studies also reported interethnic differences in the frequencies of genotype polymorphisms of the renin-angiotensin system in Chinese heart failure patients.14-16 How such information in the future can influence our treatment decisions remains to be investigated. Racial differences have recently emerged as a “surrogate maker” for underlying genetic heterogeneity. Although clinical evidence has often been extrapolated from one race to another, clinical presentations and physiologic differences can be observed in different racial cohorts. For example, in a cohort study of patients admitted with a diagnosis of heart failure, South Asian patients were found to be younger and more often had concomitant diabetes mellitus and acute ischemic heart disease than Caucasian patients.17 The recent African American Heart Failure Trial (A-HeFT) confirmed what was believed from earlier studies: that fixed-dose hydralazine-isosorbide dinitrate can be beneficial in African American patients with NYHA class III-IV heart failure.18 However, there is hardly any evidence of direct causal relationships, and therefore these associations can be plagued with selection biases (especially when racial categories are often self-reported). To date, there has been limited evidence to suggest that Chinese patients would respond differently to various heart failure medications when compared to other ethnicities. Therefore current treatment approaches in Taiwan still follow the general guidelines generated from professional societies from Western societies such as the American Heart Association and American College of Cardiology. Cultural differences In Taiwan, patients have three characteristics; those are “quick fix” culture, 19 “doctor-shopping” culture 20 and “herbal-drug preference” culture. 21-23 While these may be acceptable practices in common ailments, it can be largely detrimental in the case of heart failure. Regardless of underlying etiologies, the overall health literacy of patients in Taiwan is far lower than that of Current evidence-based treatment in heart failure: implications for Taiwan Medical therapies for heart failure Our clinical approach to heart failure is a reflection of the conceptual model applicable to the prevalent understanding of the pathophysiology. It is likely that different models may reflect different aspects of the heart failure syndrome, and the relative balance can be different with different individuals and in various clinical settings (Figure 2). The cardio-renal model highlights the importance of congestion as the therapeutic target, and provids the rational basis for the use of diuretics to control the volume status of patients with heart failure. In contrast, the cardio-circulatory model emphasizes hemodynamic alterations as the primary target, and provides the rationale for the use of vasodilators (afterload reduction) or inotropic therapy (augment contractility) to improve cardiac output in order to improve symptoms of heart failure. These two models have been widely applied as major therapeutic strategies to improve signs Figure 2. Heart failure models and related treatments. 213 Acta Cardiol Sin 2007;23:211-24 Shyh-Ming Chen et al. tions established from several clinical trial.66 Data from several clinical trials67,68 trials have also suggested that chronic right-sided pacing may actually worsen longterm cardiac performance, which has led to improved algorithms of pacing. Other major randomized trials have demonstrated mechanical dyssynchrony as an important target of therapy in some patients with heart failure over standard optimal medical therapy.69,70 However, the biggest limitation of broad adoption of ICD and cardiac resynchronized therapy (CRT) therapy remains largely related to the cost. Few communities will be able to afford to treat all patients based on evidence from outcomes trials, and the experience of broad adoption of device therapies has led to significant numbers of patients who were CRT “non-responders,” and effective defibrillation occurring only in less than 20% of implanted ICDs. Furthermore, an integrated and interdisciplinary approach facilitating optimal patient selection, device optimization and careful titration of the medical therapy in the post-implantation period is critical for maximizing the response of device therapies,71 although the exact protocols for optimization remain to be prospectively validated. Surgical therapies for heart failure There has been great promise in specialized heart failure surgical interventions, but heart transplantation remains the most effective long-term treatment for patients with refractory heart failure symptoms to date. In large transplant centers, the 1-, 5-, and 10-year survival rates averaged 85%, 70%, and 60%, respectively.72,73 Assessment of patient prognosis without transplantation can be reasonably determined by objective measurement of cardiac geometry and performance, hemodynamic abnormalities, degree of neurohormonal activation, and impairment in exercise tolerance.74 Mechanical assist devices have established clear roles as bridges to heart transplant and in the management of postcardiotomy shock. The first prospective randomized trial of long-term left ventricular assist device (LVAD) support for end-stage heart failure, the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart failure (REMATCH) Trial, showed a 48% reduction in the risk of death in the LVAD cohort. 75 Progressive LV remodeling may contribute independently to the future deterioration of LV function.76-79 Further work is needed in improving the durability of the devices and limiting complications. and symptoms of heart failure over the past three decades. However, these therapeutic strategies have yet to prevent progression of heart failure, nor have they led to prolonged life for patients with moderate to severe heart failure 26-29 except vasodilator therapy in selected patients.30 The “serendipitous” discovery of the importance of antagonizing the renin-angiotensin-aldosterone system has broadened our understanding of the so-called “neurohormonal model,” whereby over-expression of biologically active molecules that are capable of exerting toxic effects on the heart and circulation can be antagonized.31,32 Serum norepinephrine, angiotensin-II, vasopressin, and endothelin all have vasoconstrictive properties that are operative in the setting of heart failure. Overactive neurohormonal pathways, via aldosterone and vasopressin (anti-diuretic hormone), can directly result in volume retention.33 Several approaches have successfully administered adequate neurohormonal antagonism to alleviate such adverse effects without compromising the patients’ well-being (side effects of drug therapy, such as hypotension or azotemia). 34-38 These medications included: b-adrenergic blockers, angiotensin-converting enzyme (ACE) inhibitors, and aldosterone receptor antagonist. 39-41 These drugs can halt or even reverse the progressive cardiac dilatation that occurs as heart failure progresses, and many are affordable for broad adoption. Major societies have published extensive guidelines for the treatment of heart failure.42-45 These include extensive guidelines from the American College of Cardiology/American Heart Association. 42 European Society of Cardiology,43 Canadian Cardiovascular Society,44 and Heart Failure Society of America.45 These guidelines all emphasize the importance of timely and adequacy of treatment with neurohormonal antagonist, with careful monitoring and maintenance of the euvolemic state. Their recommendations are based on an impressive collection of clinical trials that establish the “evidence” for medical therapy (Table 1), and can be readily applicable in Taiwan. Device therapies for heart failure The past decade also witnessed an important shift from predominantly pharmacologic management to the broadened use of medical devices. The availability of reliable and compact implantable converter defibrillators (ICDs) has led to enormous advances through the indicaActa Cardiol Sin 2007;23:211-24 214 Heart Failure Care in Taiwan Table 1. Drugs Major guideline Major trials Comments 46-48 Digoxin Class IIa DIG trials 1.maintaining serum digoxin level 0.5~0.8 ng/mL in men, 0.5~0.9 ng/ml in women. 2.systolic dysfunction with atrial fibrillation. 3.Start digoxin despite appropriate therapy, including an ACE inhibitor, and/or beta blocker. Diuretics Class I Cochrane review49 1.furosemide, bumetanide and torsemide. 2.A continuous infusion of a loop diuretic may improve diuresis and reduce toxicity when compared to intermittent bolus injections.49 ACEI Class I CONSENSUS,50 SOLVD36 1.asymptomatic or symptomatic left ventricular dysfunction. 2.Begin therapy with low doses (e.g., 2.5 mg of enalapril twice daily, 6.25 mg of captopril three times daily, or 5 mg of lisinopril once daily). Angiotensin receptor blockade (ARB) Class IIa (Class I if ACEIs intolerant) ELITE II,51 ValHeFT,52 CHARMAdded,53 CHARMAlternative,54 VALIANT,55 ARCH-J56 1.addition of an ARB, if tolerated, to HF therapy in patients who are still symptomatic on ACE inhibitors and beta blockers. 2.an ARB should not be added to an ACE inhibitor in the immediate post-MI setting. b-blocker Class I MERIT-HF,57,58 COPERNICUS, U.S. Carvedilol Heart Failure Study,38 CIBIS II,59,60 COMET61 1.carvedilol, metoprolol, and bisoprolol. 2.equivalent survival benefit in patients with stable class IV compared with those with class II and III.38,58,60 3.improvement in survival is additive to that induced by ACE inhibitors.62 Aldosterone antagonist Class IIa (cre < 2.5 mg/dL in men, < 2.0 in women, K < 5.0 meq/L) RALES,40 EPHESUS63 1.spironolactone and eplerenone. 2.The role of aldosterone blockade in mild-to-moderate HF has not been defined, and its use is not recommended in such patients. 3.spirolactone 30% reduction in mortality, eplerenone 15% reduction in mortality in post-MI patients. Hydralazine/Isodil (ISDN-HYD) Class IIa (who are already taking an ACEIs and b-blocker for symptomatic HF) VAC,30 V-HeFT,34,64 1.Hydralazine (25 mg tid to 100 mg tid) and isosorbide dinitrate (40 mg tid or qid) or mononitrate (40 to 120 mg QD) produce modest benefit in patients with HF compared to placebo,30 and are less effective than ACE inhibitors.34 2.benefit of fixed-dose ISDN-HYD in addition to standard therapy, especially in AA.18,65 65 A-HeFT cording to the post-hoc analyses.80,81 Judicious use of diuretics is beneficial when done with careful consideration of optimal volume status. Recent attention has also focused on the contributions of unexplained anemia (or “anemia of heart failure”) in morbidity and mortality and as a potential therapeutic target.82 Indeed, administration of erythropoesis stimulating agents (such as darbepoetin-alfa) in anemic patients with heart failure has been associated with improved quality of life and Managing co-morbidities While many doctors have focused on the treatment of the heart failure syndrome, there has been more and more recognition that co-morbidities have greatly affected the clinical outcomes of patients with acute and chronic heart failure. Several important co-morbidities are worth special attention. For example, renal preservation is important both prognostically and therapeutically. Chronic diuretic therapy may be potentially harmful, ac215 Acta Cardiol Sin 2007;23:211-24 Shyh-Ming Chen et al. functional capacity,83 but larger studies are ongoing to provide conclusive evidence. Another important co-morbid condition commonly found in Taiwan is diabetes mellitus. While the primary focus of many studies has been on the impact of diabetes mellitus on coronary ischemia, it has been well established that the diabetic myocardium is prone to a wide spectrum of abnormalities, and the use of several anti-diabetic medications (such as metformin, thiazolidinedione,84-86 and even insulin) in patients with underlying heart failure has been challenging. The side-effects of fluid retention, edema and congestive heart failure have been reported in the literature with regard to the use of PPARg agonists (or thiazolidinediones). There is also relatively good documentation in the literature that thiazolidinediones do not produce adverse haemodynamic consequences. Thiazolidinediones-induced fluid retention is often sub-acute in nature, developed over weeks to months following initiation. Current approval of thiazolidinedione use in patients with mild (NYHA class I-II) and stable heart failure is supported by existing literature and clinical experience.86 To date, the appropriate goals and ranges of glycemic control in patients with advanced heart failure are still not established,87 but it is reassuring that all evidence-based medications have been shown to be equally effective in the diabetic population. Medical therapies for decompensated heart failure For most patients presenting with acute decompensated heart failure, adequate tissue perfusion and relief of congestion are still the mainstay therapeutic goals. According to the cardio-circulatory model, there are two strategies: an early and sustained reduction in filling pressures by vasodilator therapy, and in some cases an overdrive of existing contractile apparatus by inotropic therapy. These strategies were designed decades ago, and had not been rigorously tested in modern-day clinical trials. Over the past years, it is becoming clearer and clearer that vasodilators may offer a generally effective and more benign form of parenteral support for acute decompensated heart failure than inotropic therapy, as a large proportion of patients present with vascular alterations and/or diastolic dysfunction rather than worsening contractile impairment. In contrast, the weight of current evidence88,89 supports the hypothesis that drugs acting to increase intracellular cyclic adenosine monophosphate in Acta Cardiol Sin 2007;23:211-24 the myocardium are associated with adverse long-term outcomes, most prominently increased mortality. Even overzealous use of intravenous diuretics in this setting may promote rather than suppress the neurohormonal response to heart failure.90 Vasodilators have fallen out of favor with many physicians, but their beneficial effects have been well established. Nitroglycerin acts by increasing intracellular levels of cyclic guanosine monophosphate (GMP), resulting in venous and, for higher doses, arterial vasodilation. 89 The advantages of nitroglycerin include low cost, patient comfort, and a proven safety profile. Suboptimal dosing aside, there are two primary obstacles to the effective use of nitroglycerin, the phenomenon of tolerance and its effect on neurohormonal pathways. 91 Sodium nitroprusside has been proven to effectively and rapidly reduce filling pressures and increase stroke volume through venous and arterial dilation. However, the use of sodium nitroprusside requires frequent titration, and careful monitoring of hemodynamic alterations have to be achieved via a pulmonary artery catheter. The risk of thiocyanate toxicity has been widely quoted, 92 although clinically, patients appear to tolerate sodium nitroprusside infusions well. Synthetic analogues of natriuretic peptides such as nesiritide in the United States and carperitide in Japan have also been used as vasodilators with ancillary properties in the setting of acute decompensated heart failure.93 Short-term infusion of nesiritide has been shown to substantially improve hemodynamics and heart failure symptoms in a randomized, controlled comparison with nitroglycerin in patients with decompensated advanced heart failure.91,94 However, recent post-hoc meta-analyses linking nesiritide use and adverse effects, specifically, worsening renal function95 and death,96 has prompted concerns about long-term safety. The challenges to identify effective drug therapies highlight the difficulties facing clinical drug development, regulatory approval, and clinical applications, particularly in the setting of acute decompensated heart failure. The Acute Decompensated Heart Failure National Registry (ADHERE) shows that most hospitalizations for acute decompensated heart failure are due to congestion in patients refractory to oral diuretics.97 Approximately 25% to 30% of patients may develop diuretic resistance, defined as reduced diuresis and natriuresis (serum creatinine [sCr] ³ 1.5 mg/dl, high daily oral diuretic 216 Heart Failure Care in Taiwan itor patients’ volume status and titrate various heart failure medications, as well as triage and sometimes avert admissions. In Taiwan, the nursing specialists have helped make a 41.8% total cost reduction in an organized heart failure management in one University hospital.108 Second, efforts should be made to educate patients and their caregivers about the self-management of heart failure, precipitating factors, and the need for compliance with medication and dietary advice (particularly because most heart failure re-admissions are caused by factors that patients can be taught to recognize and avoid).109 Finally, there must be ready access to clinicians with an interest and expertise in treating patients with heart failure, especially in complex levels of care when faced with end-stage strategies of transplant, end-of-life issues, or mechanical support. Evidence-based practice implementation in hospital setting Despite the compelling clinical trial evidence and guideline endorsements regarding the use of ACE inhibitors and b-blockers in chronic heart failure, these agents continue to be largely underused.110 Recent trends have identified the hospital as an ideal setting for initiating these therapies, and systematic improvement in the process of care may be more effective than identifying novel therapies. For example, the Initiation Management Pre-discharge Process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-heart failure) trial demonstrated that in-hospital initiation of b-blockade resulted in a significantly greater use of b-blockers at 60 days after randomization compared with post-discharge initiation at the physician’s discretion.111 This is in contrast with clinical practice a decade ago, when b-bloc- doses [furosemide > 80 mg, torsemide > 40 mg, or bumetamide > 2 mg], or both).98 Therapies for diuretic resistance have had limited success. Ultrafiltration is an alternative treatment that has been shown to reduce right atrial and pulmonary artery wedge pressures and increase cardiac output, diuresis, and natriuresis without changes in heart rate, systolic blood pressure (SBP), renal function, electrolytes, or intravascular volume.99 Early ultrafiltration in patients with fluid overload and diuretic resistance have bee shown to favorably decrease length of stay and re-hospitalizations in high-risk heart failure patients.100 An optimal strategy utilizing continuous renal replacement therapy can dramatically improve the patient’s clinical condition, mitigate the neurohumoral stimulation, increase urinary output and promote absorption of excessive extravascular fluid.101 Improving the focus and organization of care (Figure 3) Heart failure disease management clinics Although numerous studies have shown that medications and lifestyle modifications may reduce mortality in chronic heart failure, adherence to these interventions is often below optimal levels. Granger and colleagues assessed the association between adherence and clinical outcome in the CHARM (Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity) programme. They found that good adherence to medication (> 80% of their prescribed drugs) was associated with a lower risk of death than poor adherence in patients with chronic heart failure irrespective of treatment or placebo groups.102 This is a very important observation to illustrate that discovering an effective drug can only be effective if the drug is being utilized, and compliance itself (in other words, closer attention to selfmanagement) is associated with improvement in outcomes. When studied in the context of multidisciplinary teams, often led by cardiologists, nurse specialists have been shown to contribute significantly to improving outcomes.103-105 Three elements are crucial to the success of these programs. First, specially trained nurses should be key components of any heart failure intervention.106-108 In the United States, nurses often assume the role as “specialists” who are trained to manage patients with heart failure as physician extenders, and are able to mon- Figure 3. Heart failure care algorithm. 217 Acta Cardiol Sin 2007;23:211-24 Shyh-Ming Chen et al. kers were contraindicated in the setting of acute decompensation and physicians often waited until patients became “stable” in the ambulatory care setting – in many cases without restarting. Several studies have demonstrated that in-hospital initiation of evidence-based, guideline-recommended lifesaving therapies has markedly improved treatment use, long-term patient compliance, and clinical outcomes in patients with cardiovascular disease.112,113 The benefits of in-hospital drug initiation has been confirmed by the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) program, which contains a hospital tool kit with evidence-based best practices algorithms, critical pathways, standardized orders, discharge checklists, pocket cards, chart stickers, and a variety of other elements to assist hospitals in improving heart failure management.114 Using these toolkits, increased rate of carvedilol use at discharge has been associated with an early survival benefit.115 Cardiopulmonary exercise testing (CPET) and rehabilitation CPET is a well-established tool applied in several clinical entities, and significant overlap exists in the exercise responses of patients with different respiratory and cardiac diseases.116 Peak oxygen consumption (VO2) measured during maximal exercise testing provides an objective assessment of functional capacity in patients with heart failure and an indirect assessment of cardiovascular reserve. A significant deterioration of maximal exercise performance frequently precedes clinical decompensation. Gas exchange measurements during exercise provide an accurate assessment of severity of heart failure and, by performing repeated studies, progression of disease and response to therapy. Beaver et al. developed this method, termed the V-slope method, to detect the anaerobic threshold (AT), using computerized regression analysis of the slopes of the CO2 uptake (VCO2) vs. VO2 plot, which detects the beginning of the excess CO2 output generated from the buffering of [H+].117 These parameters have been used extensively to objectively determine the need to consider for cardiac transplantation, and a value of 14 ml/min/kg has been a standard that has stood the test of time (although recently it has been challenged with the recognition that women have relatively lower VO2 for the same mortality risks).118 Recently, the VE/VCO2 slope to peak exercise was also proposed as the Acta Cardiol Sin 2007;23:211-24 one of the best predictors of mortality in patients with heart failure.119 Benefits of exercise training have been reported in skeletal muscles, respiratory and cardiovascular systems, and in their physiological responses to exercise. 120 A systematic review of 81 published studies, including 2387 exercising heart failure patients, 121 and a metaanalysis of nine randomized, parallel-controlled trials, including 801 patients, has recently concluded that properly supervised training programs are safe and associated with clear evidence of an overall reduction in mortality.122 In this setting, symptom-limited CPET has the following uses: (1) definition of exercise tolerance; (2) selection of exercise training intensity; (3) assessment of improvement in functional capacity; and (4) prognostic evaluation.123 Current challenges for Taiwan Despite increasing heart failure disease burden in Taiwan, several factors may account for a wide treatment gap between clinical practice guideline recommendations and actual clinical practice in the care of patients with heart failure. Efforts should be made for doctors in centers as well as of primary care to be aware of and familiar with the existing clinical practice guideline recommendations. In addition, the overall health literacy issue in Taiwan society may require the setting up of a nationwide registration and education program to improve the awareness of heart failure self-management. This extensive patient educational program may require the involvement of non-physician healthcare providers with direct care responsibilities in the format of disease management programs, as seen in Western societies. However, the global budget payment system challenges the resources needed to further care and education for patients with heart failure. Taiwan’s National Health Insurance (NHI) program, which was implemented in 1995, is planning a hospital case payment system to avoid unnecessary utilization. The vast discrepancies in the quality of care provided by different medical institutions have prompted the proposal of “pay for performance,” whereby reimbursements for medical services rendered is rewarded by a graded pay scale. The experience of heart failure center in National Taiwan University Hospital has demonstrated a decrease in hospital expenditure, ambulatory cli218 Heart Failure Care in Taiwan nic visiting rate, and days of hospital’s stay. The 5-year survival rate has also increased from 50% to 66%.108 The NHI in Taiwan is going to apply the concept of Diagnosis Related Groups (DRGs) throughout the health care system in 2008. Quality control will be a rising issue in the new payment system. It is suggested that the NHI should design and execute the clinical pathway along with the new DRG system to monitor and control the quality of heart failure care. The disease management program with patient education should be a necessary element in the heart failure treatment, which has been proven to be cost-effective in various literature.108 4. 5. 6. 7. CONCLUSION Heart failure is a costly disease with an increasing prevalence, and will likely pose a significant burden in the coming decades in Taiwan. Although there have been great strides in the development and application of evidence-based treatment strategies, the prognosis for patients with heart failure is still poor, in some cases worse than many of the cancer diagnoses. Changes in the concept of the heart failure syndrome have transformed this once-believed terminal illness into a manageable chronic condition, readily responsive to special therapies and counseling. However, the treatment of heart failure (as well as the organization of heart failure care) has received far lesser attention and recognition in Taiwan, in part because there is no single procedure or therapy that has been embraced by physicians specialized in taking care of patients with heart failure. The multidisciplinary approach with coordinated care is novel in Taiwan, and the training of heart failure nurse specialists and establishment of rehabilitation programs are urgently needed. 8. 9. 10. 11. 12. 13. 14. REFERENCES 15. 1. Stewart S, Jenkins A, Buchan S, et al. The current cost of heart failure to the national health service in the UK. European Journal Of Heart Failure. 2002;4:361-71. 2. Macintyre K, Capewell S, Stewart S, et al. Evidence of improving prognosis in heart failure: trends in case fatality in 66, 547 patients hospitalized between 1986 and 1995. [see comment]. Circulation. 2000;102:1126-31. 3. Jong P, Vowinckel E, Liu PP, et al. Prognosis and determinants of 16. 17. 219 survival in patients newly hospitalized for heart failure: a population-based study. [see comment]. Archives Of Internal Medicine. 2002;162:1689-94. Chen MC, Chang HW, Cheng CI, et al. Risk stratification of in-hospital mortality in patients hospitalized for chronic congestive heart failure secondary to non-ischemic cardiomyopathy. Cardiology. 2003;100:136-42. Huang CM, Young MS, Wei J. Predictors of short-term outcome in chinese patients with ambulatory heart failure for heart transplantation with ejection fraction < 25%. Japanese Heart Journal. 2000;41:349-69. Huang CH, Chien KL, Chen WJ, et al. Impact of heart failure and left ventricular function on long-term survival: report of a community-based cohort study in Taiwan. European Journal of Heart Failure. 2007;9:587-93. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics -- 2006 update: a report from the american heart association statistics committee and stroke statistics subcommittee. [erratum appears in Circulation. 2006 Apr 11;113(14):E696]. Circulation. 2006;113:E85-151. Kozak LJ, Owings MF, Hall MJ. National Hospital Discharge Survey: 2001 annual summary with detailed diagnosis and procedure data. Vital & Health Statistics - Series 13: Data from The National Health Survey. 2004;1-198. Krumholz HM, Parent EM, Tu N, et al. Readmission after hospitalization for congestive heart failure among medicare beneficiaries. [see comment]. Archives of Internal Medicine. 1997;157: 99-104. Lee CH. Efficiency of health care system in Taiwan. Taiwan J Public Health. 2003;22:89-96. Donahue MP, Marchuk DA, Rockman HA. Redefining heart failure: the utility of genomics. [Review] [78 Refs]. J Am Coll Cardiol. 2006;48:1289-98. Chiang FT, Hsu KL, Tseng CD, et al. Association of the renin gene polymorphism with essential hypertension in a Chinese population. Clinical Genetics. 1997;51:370-4. Tsai CT, Fallin D, Chiang FT, et al. Angiotensinogen Gene Haplotype and Hypertension: Interaction with ACE Gene I Allele. Hypertension. 2003;41:9-15. Sanderson JE, Yu CM, Young RP, et al. Influence of gene polymorphisms of the renin-angiotensin system on clinical outcome in heart failure among the Chinese. American Heart Journal. 1999;137:653-7. Huang W, Xie C, Zhou H, et al. Association of the angiotensin-converting enzyme gene polymorphism with chronic heart failure in Chinese Han patients. European Journal Of Heart Failure. 2004;6:23-7. Sanderson JE, Young RP, Yu CM, et al. Lack of association between insertion/deletion polymorphism of the angiotensin-converting enzyme gene and end-stage heart failure due to ischemic or idiopathic dilate cardiomyopathy in the Chinese. American Journal of Cardiology. 1996;77:1008-10. Blackledge HM, Newton J, Squire IB. Prognosis for South Asian Acta Cardiol Sin 2007;23:211-24 Shyh-Ming Chen et al. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. and white patients newly admitted to hospital with heart failure in the United Kingdom: historical cohort study. BMJ. 2003;327: 526-31. Taylor AL. The African American Heart Failure Trial: A clinical trial update. [Review] [26 Refs]. American Journal of Cardiology. 2005;96:44-8. Chen YC. Chinese values, health and nursing. [Review] [20 refs]. Journal of Advanced Nursing. 2001;36:270-3. Chen TJ, Chou LF, Hwang SJ. Patterns of ambulatory care utilization in Taiwan. BMC Health Services Research. 2006;6:54. Lew-Ting CY. Antibiomedicine belief and integrative health seeking in Taiwan. Social Science & Medicine. 2005;60:2111-6. Lee CH, Chen JJ, Liang WM. Attitudes and intentions of patients toward integrated Chinese and Western medicine In Taiwan. Journal of Alternative & Complementary Medicine. 2006;12: 233-6. Chen FP, Chen TJ, Kung YY, et al. Use frequency of traditional Chinese medicine In Taiwan. BMC Health Services Research. 2007;7:26. Huang YM, Wang HP, Yang YH, et al. Effects of a national health education program on the medication knowledge of the public in Taiwan. Annals of Pharmacotherapy. 2006;40:102-8. Shih FJ. Concepts related to Chinese patients’ perceptions of health, illness and person: issues of conceptual clarity. [Review] [26 refs]. Accident & Emergency Nursing. 1996;4:208-15. Francis GS, Siegel RM, Goldsmith SR, et al. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure: activation of the neurohumoral axis. Annals of Internal Medicine. 1985;103:1-6. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol. 1992;20:248-54. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure: the PROMISE study research group. [see comment]. New England Journal of Medicine. 1991;325:1468-75. Massie BM. 15 years of heart-failure trials: what have we learned? [Review] [33 refs]. Lancet. 1998;352:Suppl-33. Cohn JN, Archibald DG, Ziesche S et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. New England Journal of Medicine. 1986;314:1547-52. Bristow MR. The adrenergic nervous system in heart failure. New England Journal of Medicine. 1984;311:850-1. Tan LB, Jalil JE, Pick R, et al. Cardiac myocyte necrosis induced by angiotensin II. Circulation Research. 1991;69:1185-95. Bristow MR. The adrenergic nervous system in heart failure. New England Journal of Medicine. 1984;311:850-1. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. [see comment]. New England Journal of Medicine. 1991;325:303-10. Effect of enalapril on survival in patients with reduced left ven- Acta Cardiol Sin 2007;23:211-24 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 220 tricular ejection fractions and congestive heart failure: the SOLVD Investigators. [see comment] New England Journal of Medicine. 1991;325:293-302. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions: the SOLVD Investigattors. [see comment] [erratum appears in N Engl J Med 1992 Dec 10;327(24):1768] New England Journal of Medicine. 1992;327:685-91. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. [see comment] [comment]. Circulation. 1996;94:2807-16. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. [see comment]. New England Journal of Medicine. 1996;334:1349-55. Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. [see comment]. Lancet. 2000;355:1575-81. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. [see comment]. New England Journal of Medicine. 1999;341:709-17. Foody JM, Farrell MH, Krumholz HM. Beta-blocker therapy in heart failure: scientific review. [Review] [98 refs]. JAMA. 2002; 287:883-9. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005;112: E154-E235. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26:1115-40. Arnold JM, Liu P, Demers C, et al. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. [erratum appears in Can J Cardiol. 2006 Mar 1;22(3):271]. [171 refs]. Canadian Journal of Cardiology. 2006;22:23-45. Heart Failure Society of America. Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. [Review] [105 refs]. Journal of Cardiac Failure. 2006;12:10-38. The effect of digoxin on mortality and morbidity in patients with heart failure: the Digitalis Investigation Group. [see comment] Heart Failure Care in Taiwan New England Journal of Medicine. 1997;336:525-33. 47. Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. [see comment]. JAMA. 2003;289:871-8. 48. Adams KF, Jr., Patterson JH, Gattis WA, et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. [see comment]. J Am Coll Cardiol. 2005;46:497-504. 49. Salvador DR, Rey NR, Ramos GC, et al. Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. [update of Cochrane Database Syst Rev. 2004;(1):CD003178; PMID: 14974008]. [Review] [31 refs]. Cochrane Database of Systematic Reviews. 2005;CD003178. 50. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS): the CONSENSUS Trial Study Group New England Journal of Medicine. 1987;316:1429-35. 51. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial -- the Losartan Heart Failure Survival Study ELITE II. [see comment]. Lancet. 2000;355:1582-7. 52. Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. [see comment] [summary for patients in J Card Fail. 2002 Apr;8(2):56-8; PMID: 12016625]. New England Journal of Medicine. 2001;345:1667-75. 53. Mcmurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-convertingenzyme inhibitors: the CHARM-Added trial. [see comment]. Lancet. 2003;362:767-71. 54. Granger CB, Mcmurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. [see comment]. Lancet. 2003;362:772-6. 55. Pfeffer MA, Mcmurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. [see comment] [erratum appears in N Engl J Med. 2004 Jan 8;350(2):203]. New England Journal of Medicine. 2003;349:1893-906. 56. Matsumori A, Assessment of Response to Candesartan in Heart Failure in Japan (ARCH-. Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure. [erratum appears in Eur J Heart Fail. 2004 Jun;6(4):523]. European Journal of Heart Failure. 2003;5:669-77. 57. Effect of metoprolol cr/xl in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) [see comment] Lancet. 1999;353:2001-7. 58. Goldstein S, Fagerberg B, Hjalmarson A, et al. Metoprolol controlled release/extended release in patients with severe heart failure: analysis of the experience in the MERIT-HF study. J Am Coll Cardiol. 2001;38:932-8. 59. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. [see comment] Lancet. 1999;353:9-13. 60. Leizorovicz A, Lechat P, Cucherat M, et al. Bisoprolol for the treatment of chronic heart failure: a meta-analysis on individual data of two placebo-controlled studies -- CIBIS And CIBIS II. Cardiac Insufficiency Bisoprolol Study. American Heart Journal. 2002;143:301-7. 61. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. [see comment]. Lancet. 2003;362:7-13. 62. Exner DV, Dries DL, Waclawiw MA, et al. Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol. 1999;33:916-23. 63. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. [see comment] [erratum appears In N Engl J Med. 2003 May 29;348(22):2271]. New England Journal of Medicine. 2003;348:1309-21. 64. Carson P, Ziesche S, Johnson G, et al. Racial differences in response to therapy for heart failure: analysis of the vasodilatorheart failure trials. Vasodilator-Heart Failure Trial Study Group. Journal of Cardiac Failure. 1999;5:178-87. 65. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. [see comment] [erratum appears in N Engl J Med. 2005 Mar 24;352(12): 1276]. New England Journal of Medicine. 2004;351:2049-57. 66. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. [see comment] [erratum appears in N Engl J Med. 2005 May 19;352(20):2146]. New England Journal of Medicine. 2005; 352:225-37. 67. Wilkoff BL, Cook JR, Epstein AE, et al. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber And VVI Implantable Defibrillator (DAVID) Trial. [see comment]. JAMA. 2002;288:3115-23. 68. Sweeney MO, Hellkamp AS, Ellenbogen KA, et al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation. 2003;107:2932-7. 69. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. [see comment]. New England Journal of Medicine. 2005;352:153949. 70. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. [see comment]. New England Journal of Medicine. 2004;350:2140-50. 71. Singh JP, Ruskin JN. Cardiac resynchronization therapy: the 221 Acta Cardiol Sin 2007;23:211-24 Shyh-Ming Chen et al. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81. 82. 83. 84. MGH experience. Annals of Noninvasive Electrocardiology. 2005;10:Suppl-54. Hosenpud JD, Bennett LE, Keck BM, et al. The Registry of the International Society for Heart And Lung Transplantation: eighteenth Official Report-2001. The Journal of Heart and lung transplantation: the official publication of the International Society for Heart Transplantation. 2001;20:805-15. Trulock EP, Edwards LB, Taylor DO et al. The Registry of the International Society for Heart and Lung Transplantation: twentyfirst official adult lung and heart-lung transplant report--2004. The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation. 2004;23:804-15. Hunt SA, Frazier OH. Mechanical circulatory support and cardiac transplantation. [Review] [103 refs]. Circulation. 1998;97:207990. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term mechanical left ventricular assistance for end-stage heart failure. [see comment] [summary for patients in J Card Fail. 2002 Apr; 8(2):59-60; PMID: 12016626]. New England Journal of Medicine. 2001;345:1435-43. Cohn JN. Structural basis for heart failure. Ventricular remodeling and its pharmacological inhibition. [comment]. Circulation. 1995;91:2504-7. Douglas PS, Morrow R, Ioli A, et al. Left ventricular shape, afterload and survival in idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1989;13:311-5. Vasan RS, Larson MG, Benjamin EJ, et al. Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction. [see comment]. New England Journal of Medicine. 1997;336:1350-5. Birks EJ, Tansley PD, Hardy J, et al. Left ventricular assist device and drug therapy for the reversal of heart failure. [see comment]. New England Journal of Medicine. 2006;355:1873-84. Ahmed A, Husain A, Love TE, et al. Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J. 2006;27:1431-9. Domanski M, Tian X, Haigney M, et al. Diuretic use, progressive heart failure, and death in patients in the DIG study. [see comment]. Journal of Cardiac Failure. 2006;12:327-32. Silverberg DS, Wexler D, Blum M, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol. 2000;35:1737-44. Cleland JG, Coletta AP, Nikitin NP, et al. Clinical trials update from the American College Of Cardiology: Darbepoetin alfa, ASTEROID, UNIVERSE, paediatric carvedilol, UNLOAD and ICELAND. European Journal of Heart Failure. 2006;8:326-9. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: A Consensus Statement from the American Heart Association and American Acta Cardiol Sin 2007;23:211-24 Diabetes Association. Circulation. 2003;108:2941-8. 85. Aguilar D, Bozkurt B, Pritchett A, et al. The impact of thiazolidinedione use on outcomes in ambulatory patients with diabetes mellitus and heart failure. J Am Coll Cardiol. 2007;50:32-6. 86. Tang WHW, Maroo A. PPARgamma agonists: safety issues in heart failure. Diabetes, Obesity and Metabolism. 2007;9:447454. 87. Eshaghian S, Horwich TB, Fonarow GC. An unexpected inverse relationship between hba1c levels and mortality in patients with diabetes and advanced systolic heart failure. American Heart Journal. 2006;151:91. 88. Cuffe MS, Califf RM, Adams KF Jr., et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. [see comment]. JAMA. 2002;287:1541- 7. 89. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. [see comment] [erratum appears in JAMA 2002 Aug 7;288(5):577]. JAMA. 2002;287:153140. 90. Bayliss J, Norell M, Canepa-Anson R, et al. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. British Heart Journal. 1987;57:17-22. 91. Elkayam U, Akhter MW, Singh H, et al. Comparison of effects on left ventricular filling pressure of intravenous nesiritide and high-dose nitroglycerin in patients with decompensated heart failure. American Journal of Cardiology. 2004;93:237-40. 92. Nohria A, Lewis E, Stevenson LW. Medical management of advanced heart failure. [see comment]. [Review] [99 refs]. JAMA. 2002;287:628-40. 93. Mcmurray J, Pfeffer MA. New therapeutic options in congestive heart failure: Part II. [Review] [53 refs]. Circulation. 2002;105: 2223-8. 94. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial JAMA: the journal of the American Medical Association. 2002; 287:1531-40. 95. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005;111:1487-91. 96. Sackner-Bernstein JD, Kowalski M, Fox M, et al. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA: the journal of the American Medical Association. 2005;293: 1900-5. 97. Adams KF, Jr., Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). American Heart Journal. 2005;149:209-16. 98. Ellison DH. Diuretic therapy and resistance in congestive heart failure. Cardiology. 2001;96:132-43. 222 Heart Failure Care in Taiwan 99. Agostoni P, Marenzi G, Lauri G, et al. Sustained improvement in functional capacity after removal of body fluid with isolated ultrafiltration in chronic cardiac insufficiency: failure of furosemide to provide the same result. American Journal Of Medicine. 1994; 96:191-9. 100.Costanzo MR, Saltzberg M, O’Sullivan J, et al. Early ultrafiltration in patients with decompensated heart failure and diuretic resistance. [see comment]. J Am Coll Cardiol. 2005;46: 2047-51. 101.Sharma A, Hermann DD, Mehta RL. Clinical benefit and approach of ultrafiltration in acute heart failure. [Review] [53 refs]. Cardiology. 2001;96:144-54. 102.Granger BB, Swedberg K, Ekman I, et al. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. [see comment]. Lancet. 2005;366:2005-11. 103.Rich MW, Beckham V, Wittenberg C, et al. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med. 1995;333:1190-5. 104.Mcalister FA, Stewart S, Ferrua S, et al. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. [see comment]. [Review] [46 refs]. J Am Coll Cardiol. 2004;44:810-9. 105.Fonarow GC. Heart failure disease management programs: not a class effect. [comment]. Circulation. 2004;110:3506-8. 106.Sisk JE, Hebert PL, Horowitz CR, et al. Effects of nurse management on the quality of heart failure care in minority communities: a randomized trial. [summary for patients in Ann Intern Med. 2006 Aug 15;145(4):I28; PMID: 16908913]. Annals of Internal Medicine. 2006;145:273-83. 107.Cleland JG, Louis AA, Rigby AS, et al. Noninvasive home telemonitoring for patients with heart failure at high risk of recurrent admission and death: the Trans-European Network-HomeCare Management System (TEN-HMS) study. [see comment]. J Am Coll Cardiol. 2005;45:1654-64. 108.Ho YL, Hsu TP, Chen CP, et al. Improved cost-effectiveness for management of chronic heart failure by combined home-based intervention with clinical nursing specialists. Journal of the Formosan Medical Association. 2007;106:313-9. 109.Tsuyuki RT, Mckelvie RS, Arnold JM, et al. Acute precipitants of congestive heart failure exacerbations. Archives of Internal Medicine. 2001;161:2337-42. 110.Fonarow GC. The role of in-hospital initiation of cardioprotective therapies to improve treatment rates and clinical outcomes. [Review] [34 refs]. Reviews in Cardiovascular Medicine. 2002;3: Suppl-S10. 111.Gattis WA, O'Connor CM, Gallup DS, et al. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. J Am Coll Cardiol. 2004;43:1534-41. 112.Fonarow GC, Gawlinski A, Moughrabi S, et al. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). American Journal of Cardiology. 2001;87:819-22. 113.Fonarow GC, Ballantyne CM. In-hospital initiation of lipid-lowering therapy for patients with coronary heart disease: the time is now. Circulation. 2001;103:2768-70. 114.Fonarow GC, Abraham WT, Albert NM, et al. Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design. American Heart Journal. 2004;148:43-51. 115.Wagoner LE, Starling RC, O'Connor CM. Cardiac Function and Heart Failure. J Am Coll Cardiol. 2006;47:D18-D22. 116.American Thoracic Society, American College of Chest Physicians. ATS/ACCP Statement on cardiopulmonary exercise testing. [see comment] [erratum appears in Am J Respir Crit Care Med. 2003 May 15;1451-2]. [Review] [545 refs]. American Journal of Respiratory & Critical Care Medicine. 2003;167:211-77. 117.Beaver WL, Wasserman K, Whipp BJ. A new method for detecting anaerobic threshold by gas exchange. Journal of Applied Physiology. 1986;60:2020-7. 118.Mancini DM, Eisen H, Kussmaul W, et al. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation. 1991; 83:778-86. 119.Bard RL, Gillespie BW, Clarke NS, et al. Determining the best ventilatory efficiency measure to predict mortality in patients with heart failure. Journal of Heart & Lung Transplantation. 2006;25:589-95. 120.Coats AJ, Adamopoulos S, Meyer TE, et al. Effects of physical training in chronic heart failure. [see comment]. Lancet. 1990; 335:63-6. 121.Smart N, Marwick TH. Exercise training for patients with heart failure: a systematic review of factors that improve mortality and morbidity. [see comment]. [Review] [108 refs]. American Journal of Medicine. 2004;116:693-706. 122.Piepoli MF, Davos C, Francis DP, et al. Exercise training metaanalysis of trials in patients with chronic heart failure (ExTraMATCH). [see comment]. BMJ. 2004;328:189. 123.Task Force of the Italian Working Group on Cardiac Rehabilitation and Prevention. Statement on cardiopulmonary exercise testing in chronic heart failure due to left ventricular dysfunction: recommendations for performance and interpretation. European Journal of Cardiovascular Prevention & Rehabilitation. 2006; 13:10-12. 223 Acta Cardiol Sin 2007;23:211-24 Review Acta Cardiol Sin 2007;23:211−24 改善心臟衰竭病人的治療 臺灣可以更進步 陳世明 1 陳勉成 1 W. H. Wilson Tang2 高雄縣 高雄長庚紀念醫院 心臟內科 長庚大學醫學院1 美國俄亥俄州克里夫蘭醫院 心臟內科2 心臟衰竭是一個成長中的全世界性問題,由於心臟疾病治療的改善以及心臟衰竭治療的日 趨複雜,我們必須正視此問題的重要性,若不妥善處理,無論病人數及其花費將節節攀升, 此篇綜論主要討論西方國家與台灣在心臟衰竭治療之異同,在不同的面向上討論我們有那 些地方可以改善並進而增進病人的福祉。 關鍵詞:心臟衰竭、臺灣、整合治療。 224